Back to search results

Genetic Analysis for Pheochromocytomas and Paragangliomas

This study is looking into the genes involved in pheochromocytomas and paragangliomas (types of tumors that can produce hormones). Researchers will screen your germline (inherited) and/or tumor samples for genetic changes. The goal is to find new genes linked to these tumors and understand how different genetic changes affect the disease. You can join if you or a family member have been diagnosed with pheochromocytoma, paraganglioma, or a related condition. The study aims to identify these genetic changes, which could take about 6 months. The recruitment status is currently unclear.

Study design
This is an observational study planning to enroll 2000 participants. It is not testing a new treatment but rather observing genetic information.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goals of identifying genetic mutations are measured through study completion, which is estimated to be around 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03160274

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

Recruiting
Not specifiedAll AgesObservational
The University of Texas Health Science Center at San Antonio
~2,000 participants
Updated 2025-10-15 on ClinicalTrials.gov
What's tested:Genetic screening

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identification of germline driver mutation
Measured over through study completion- average time approximately 6 months
+1 more outcome measured

Conditions

Pheochromocytoma
Paraganglioma
Inherited Cancer Syndrome
Associated Conditions
Kidney Neoplasms
Bone Cancer
Thyroid Neoplasms
Other Cancer

Explore related trials

Adrenal Gland PheochromocytomaInherited Cancer SyndromeKidney NeoplasmMalignant Bone NeoplasmParagangliomaThyroid Gland Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Patricia L Dahia, MD, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio

Who to contact

Patricia L Dahia, MD,PhD
[email protected]
2105674866
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

diagnosis of pheochromocytoma and or paraganglioma
family member with diagnosis of pheochromocytoma and or paraganglioma
diagnosis of a pheochromocytoma- and or paraganglioma-associated condition
family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition

Exclusion

unconfirmed diagnosis of pheochromocytoma and/or paraganglioma or associated condition

What this trial measures

  • Identification of germline driver mutationthrough study completion- average time approximately 6 months

    Genetic screen detects a mutation that is likely responsible for tumor development

  • Identification of somatic driver mutationthrough study completion- average time approximately 6 months

    Genetic screen detects a mutation that is likely responsible for tumor development